This trial will study whether the drug Cabozantinib can help patients with incurable germ cell tumors. Treatment will continue until the disease progresses, the patient can't tolerate the side effects, or the study ends.
- Germ Cell Tumors
- Ovarian Germ Cell Tumor
- Non-Seminomatous Germ Cell Tumors
1 Primary · 4 Secondary · Reporting Duration: Start of the treatment until time of death or last follow up visit (up to 2 years)
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
50 Total Participants · 1 Treatment Group
Primary Treatment: Cabozantinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age Any Age · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the Cabozantinib drug's regulatory status?
"Because there is only limited data supporting Cabozantinib's safety, it received a score of 2." - Anonymous Online Contributor
What medical conditions does Cabozantinib usually address?
"Patients that have received anti-VEGF treatment, those with advanced renal cell carcinoma (aRCC), and those with adrenal medulla can all be treated using Cabozantinib." - Anonymous Online Contributor
How many people fit the eligibility requirements for this clinical trial?
"That is correct. The clinical trial, which was originally posted on 6/10/2021 and most recently edited on 11/16/2022, is presently recruiting participants, as stated on clinicaltrials.gov. This particular trial is looking for 50 patients at 1 location." - Anonymous Online Contributor
What is the efficacy of Cabozantinib in comparison to other treatments?
"As of right now, there are 116 ongoing clinical trials that involve Cabozantinib with 13 being in Phase 3. A large number of these research studies are based in Cordoba and Calabria, but there are also 7150 other locations around the world conducting similar investigations." - Anonymous Online Contributor
Are researchers looking for new participants in this trial right now?
"That is accurate. The information available on clinicaltrials.gov indicates that this study, which was first announced on June 10th 2021, is still actively seeking patients for enrollment. A total of 50 individuals are needed at a single site." - Anonymous Online Contributor
Has this type of research been done before?
"Since 2012, there have been 116 ongoing clinical trials for cabozantinib in 1375 cities and 46 countries. The initial study was conducted in 2012 by Exelixis and involved 86 patients. After the first trial, cabozantinib received Phase 2 drug approval." - Anonymous Online Contributor